Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Subscribe To Our Newsletter & Stay Updated
